Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Peritoneal Clear Cell Adenocarcinoma: full-pipeline trial registry
2 of 2 indexed Primary Peritoneal Clear Cell Adenocarcinoma trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Primary Peritoneal Clear Cell Adenocarcinoma: 2 US clinical trials tracked, 2 recruiting.
Primary Peritoneal Clear Cell Adenocarcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Roswell Park Cancer Institute, running 1 of these trials.
Enrollment posture brief
Registry condition primary-peritoneal-clear-cell-adenocarcinoma
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Primary Peritoneal Clear Cell Adenocarcinoma lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Peritoneal Clear Cell Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Peritoneal Clear Cell Adenocarcinoma is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
M.D. Anderson Cancer Center
NCT04575935
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
NCT04919629
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Peritoneal Clear Cell Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Peritoneal Clear Cell Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Peritoneal Clear Cell Adenocarcinoma page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Primary Peritoneal Clear Cell Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Roswell Park Cancer Institute sponsors the most Primary Peritoneal Clear Cell Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See Roswell Park Cancer Institute's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Peritoneal Clear Cell Adenocarcinoma condition card totals 2 registered trials; most-linked intervention Laparotomy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.